Healthcare
•3759 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3759)
| Company | Market Cap | Price |
|---|---|---|
|
PTCT
PTC Therapeutics, Inc.
PTC Therapeutics operates primarily in rare diseases across multiple programs, a core focus.
|
$6.85B |
$86.24
-0.01%
|
|
VOYA
Voya Financial, Inc.
VOYA provides health insurance products and related stop‑loss/health solutions to employers, a central part of its Workplace Solutions.
|
$6.81B |
$70.63
-0.04%
|
|
BTSG
BrightSpring Health Services, Inc. Common Stock
Company operates home health and hospice services to patients in home and community settings.
|
$6.46B |
$36.47
+0.69%
|
|
PCVX
Vaxcyte, Inc.
PCVX directly develops and is advancing vaccine products (VAX-24, VAX-31) including pneumococcal conjugate vaccines, making Vaccines the core investable product category.
|
$6.45B |
$49.67
-1.13%
|
|
CHE
Chemed Corporation
Chemed's VITAS Hospice provides direct home health and hospice care services.
|
$6.43B |
$441.25
+0.12%
|
|
RDNT
RadNet, Inc.
RadNet operates outpatient imaging centers/ASC, providing diagnostic imaging services.
|
$6.37B |
$82.79
|
|
KRYS
Krystal Biotech, Inc.
Krystal Biotech's core HSV-1 gene therapy platform and lead product VYJUVEK directly represent a gene therapy business.
|
$6.33B |
$218.97
+0.12%
|
|
LTH
Life Time Group Holdings, Inc.
MIORA longevity clinics and other healthcare services are provided as part of the ecosystem.
|
$6.14B |
$27.91
+1.33%
|
|
MIR
Mirion Technologies, Inc.
Core business: Mirion designs and manufactures medical devices and biometric sensing equipment used in radiology, radiation therapy, and nuclear medicine.
|
$6.05B |
$25.86
+1.73%
|
|
GKOS
Glaukos Corporation
Glaukos directly manufactures ophthalmology devices, including iStent MIGS implants used in eye surgeries.
|
$6.04B |
$105.44
+1.04%
|
|
GRFS
Grifols, S.A.
Grifols operates as a large, global pharmaceutical company with a core focus on plasma-derived therapies.
|
$6.04B |
$8.78
+1.27%
|
|
IRTC
iRhythm Technologies, Inc.
Direct product: iRhythm's patch-based patient monitoring device and associated software for continuous cardiac monitoring.
|
$6.00B |
$186.59
-0.04%
|
|
BLCO
Bausch + Lomb Corporation
Ophthalmology Devices – direct manufacture and sale of eye-care surgical devices and related ophthalmic equipment.
|
$5.73B |
$16.22
+0.12%
|
|
COGT
Cogent Biosciences, Inc.
Cogent's lead asset bezuclastinib and the described pipeline assets are primarily oral small-molecule tyrosine kinase inhibitors, i.e., Oral Small Molecule Therapeutics.
|
$5.64B |
$40.38
-0.02%
|
|
OLED
Universal Display Corporation
Contract research services via Adesis subsidiary.
|
$5.62B |
$118.20
-0.01%
|
|
PTGX
Protagonist Therapeutics, Inc.
Direct product category: PTGX's core business is peptide therapeutics.
|
$5.60B |
$90.08
+0.25%
|
|
CDTX
Cidara Therapeutics, Inc.
CD388 is an antiviral small-molecule therapeutic targeting neuraminidase for universal influenza prevention and treatment.
|
$5.57B |
$219.76
+0.00%
|
|
ESE
ESCO Technologies Inc.
Diagnostic Equipment reflects ESCO's diagnostic testing instruments and related software for measurement and monitoring.
|
$5.50B |
$212.90
-2.09%
|
|
RGC
Regencell Bioscience Holdings Limited
Regencell Bioscience focuses on neuropsychiatric drug development for ADHD/ASD, aligning with Neuropsychiatric Drug Development.
|
$5.49B |
$11.40
+2.61%
|
|
UNMA
Unum Group 6.250% JR NT58
Disability insurance is a core component of Unum's financial protection offerings in workplace benefits.
|
$5.38B |
$23.77
+0.38%
|
|
TGTX
TG Therapeutics, Inc.
BRIUMVI is TG Therapeutics' flagship monoclonal antibody therapeutic (anti-CD20) for relapsing MS, the core product driving revenue and growth.
|
$5.30B |
$33.41
+1.32%
|
|
VNT
Vontier Corporation
Repair Solutions includes diagnostic equipment launches for vehicle repair workflows.
|
$5.24B |
$35.72
+0.06%
|
|
MMSI
Merit Medical Systems, Inc.
Vascular/interventional devices focus, including WRAPSODY endoprosthesis for dialysis access.
|
$5.18B |
$87.43
-0.19%
|
|
TFX
Teleflex Incorporated
Teleflex is a global medical device company designing, manufacturing, and selling single-use medical devices across critical care, surgical, and interventional markets.
|
$5.09B |
$115.33
+0.03%
|
|
LEGN
Legend Biotech Corporation
CARVYKTI is a CAR-T cell therapy and Legend Biotech's flagship product, representing its direct cell-therapy manufacturing and commercialization activity.
|
$5.04B |
$27.50
-2.43%
|
|
OPCH
Option Care Health, Inc.
OPCH delivers home health infusion and hospice-related services in patients' homes, aligning with home health care offerings.
|
$5.03B |
$31.04
-0.59%
|
|
GNTX
Gentex Corporation
Medical Devices & Biometrics covers EyeLock iris biometrics and eSight medical device initiatives tied to Gentex's diversification.
|
$4.99B |
$22.73
-0.02%
|
|
TMDX
TransMedics Group, Inc.
TransMedics' Organ Care System (OCS) is a proprietary medical device platform for organ preservation and monitoring.
|
$4.97B |
$145.84
-0.11%
|
|
SHC
Sotera Health Company
Nelson Labs provides outsourced microbiological and analytical chemistry testing plus regulatory advisory services.
|
$4.95B |
$17.45
+0.06%
|
|
ALKS
Alkermes plc
Direct product category encompassing Alkermes' oral small-molecule therapeutics, including LYBALVI.
|
$4.91B |
$29.72
+2.52%
|
|
KYMR
Kymera Therapeutics, Inc.
Kymera's core offering is oral small molecule therapeutics designed to degrade disease-causing proteins (STAT6, IRAK4, IRF5) in immunology indications.
|
$4.85B |
$67.81
-0.07%
|
|
CRSP
CRISPR Therapeutics AG
CRISPR-based ex vivo gene-editing therapy CASGEVY is a gene therapy product.
|
$4.85B |
$53.30
-0.01%
|
|
GHC
Graham Holdings Company
Healthcare Services & Facilities reflecting CSI Pharmacy and patient services.
|
$4.76B |
$1090.90
+0.17%
|
|
WGS
GeneDx Holdings Corp.
Laboratory testing services and advisory components of genetic diagnostics.
|
$4.76B |
$165.51
-0.06%
|
|
OSCR
Oscar Health, Inc.
Core product is health insurance plans via ACA marketplace and employer-based offerings, generating premium-based revenue.
|
$4.70B |
$18.16
+8.52%
|
|
INDV
Indivior PLC
SUBLOCADE's extended-release delivery represents a drug delivery platform (monthly dosing), a core investable theme.
|
$4.62B |
$33.47
-0.03%
|
Showing page 7 of 38 (3759 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
